Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

49P - A phase II trial of nivolumab and gemcitabine and S-1 as the first-line treatment in patients with advanced biliary tract cancer

Date

16 Sep 2021

Session

ePoster Display

Presenters

Nai-Jung Chiang

Citation

Annals of Oncology (2021) 32 (suppl_5): S376-S381. 10.1016/annonc/annonc685

Authors

N. Chiang1, L. Bai2, C. Huang3, S. Chen4, C. Hsiao5, Y. Shan6, Y. Su1, L. Chen1, M. Chen4

Author affiliations

  • 1 National Institute Of Cancer Research, National Health Reseatch Institutes, 701 - Tainan City/TW
  • 2 Department Of Internal Medicine, China Medical University Hospital, Taichung/TW
  • 3 Department Of Internal Medicine, National Cheng Kung University Hospital, Tainan/TW
  • 4 Department Of Oncology, Taipei Veterans General Hospital, Taipei/TW
  • 5 National Helath Research Institutes, Institute of Population Health Sciences, Zhunan/TW
  • 6 Department Of Surgery, National Cheng Kung University Hospital, Tainan/TW
More

Abstract 49P

Background

The regimen of modified gemcitabine and S-1 (GS) is active and safe for patients with advanced biliary tract cancer (ABTC) in our previous study. Herein, we report the results of a single arm phase II of Nivolumab plus modified GS as the first-line treatment in ABTC patients.

Methods

Patients with chemonaïve ABTC receive nivolumab 240 mg and 800 mg/m2 gemcitabine on day 1 plus daily 80/100/120 mg of S-1 (based on body surface area) for days 1-10, in a 2-week cycle. With Optimal Simon’s two-stage design and (p0=0.15, p1=0.35) for objective response rate (ORR, complete or partial response [CR/PR]) and given error probabilities (alpha=0.05, beta=0.1), the null hypothesis (p0) would be rejected if 10 or more patients had CR/PR among 44 evaluable cases. Tumor response was assessed by CT/MRI every 6 weeks according to RECIST v1.1. The PR should be confirmed by two consecutive image examinations.

Results

Between December 2019 and December 2020, a total of 48 patients were enrolled. After a median of 6.4 months (95% CI, 4.8-8.0) follow-up, 1 patient showed pathological CR and 19 patients achieved confirmed PR. The ORR was 41.7% with additional 22 patients (45.8%) of stable disease and a long-term disease control rate of 77.1% (CR+PR+SD >12weeks). The median progression-free survival and overall survival was 8.0 (95% CI, 5.8-not reached) and not reached (95% CI, 10.7-not reached) months, respectively. All grade 3/4 chemotherapy-related adverse events (AEs) were less than 7%. Fourteen patients (35.4%) experienced immune-related AEs with skin toxicity (14.6%), hypothyroidism, hypophysitis and pneumonitis (all 6.3%). Two patients with grade 3 pneumonitis recovered well without any treatment-related death.

Conclusions

By the observation of 20 patients with CR/PR, the null hypothesis was rejected. Nivolumab in combination with modified GS is a promising regimen with good safety profiles, which deserves further investigation for the management of Asian ABTC patients.

Clinical trial identification

Trial registration number NCT04172402.

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Ono Pharmaceutical support Nivolumab.

Disclosure

L. Bai: Non-Financial Interests, Personal, Advisory Board: Bristol-Myers Squibb; Financial Interests, Personal, Other, Honoraria: Syncore, Pfizer, Lilly. L. Chen: Non-Financial Interests, Personal, Leadership Role: ScinoPharm Taiwan, Ltd.; Non-Financial Interests, Personal, Other, Honoraria: PharmaEngine, Taivex, OBI; Non-Financial Interests, Personal, Sponsor/Funding: Syncore, TTY, Pfizer, BMS, Novartis, Polaris, Merck Serono, ACTgenomics; Non-Financial Interests, Personal, Other, Patent: anti-alpha enolase (ENO-1) monoclonal antibody/HuniLife. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.